From March 11 to 14, the 7th Vaccine Innovation Forum (VIF World 2026) was held in Shanghai. The forum brought together over a thousand industry experts, representatives from research institutions, and corporate executives from more than 30 countries and regions, including over 150 industry leaders and top scientists, to engage in in-depth discussions on vaccine innovation, industry collaboration, and global public health challenges.

Image source: VIF World 2026

Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, was invited to attend the forum and share his insights. Drawing on the company's experience in vaccine R&D, CMC full lifecycle management, and global supply chain and vaccine supply management, he emphasized that advancing vaccine innovation requires not only technological breakthroughs but also early-stage planning that integrates industrialization pathways, supply chain capabilities, and end-use scenarios, ensuring that innovations are translated into accessible and usable public health products.

Image source: VIF World 2026

He cited CanSinoBIO's development of the recombinant Ebola vaccine (adenovirus vector) in response to the West African Ebola outbreak as an example, highlighting that cold chain requirements and infrastructure remain major bottlenecks affecting vaccine accessibility. Some vaccines rely heavily on cold chain storage, presenting challenges in regions with limited infrastructure. For instance, in certain African areas, maintaining vaccine storage requires battery systems and diesel generators, significantly increasing overall costs. In some regions, vaccine transportation also faces complex geographic and logistical challenges, such as navigating through jungles while managing multi-dose administration requirements. These factors demonstrate that even after successful R&D, achieving large-scale vaccination remains a substantial challenge.

Dr. Yu emphasized that in the life sciences, innovation is not only about technological breakthroughs but also about translating scientific achievements into accessible and scalable solutions that effectively improve health outcomes across countries and regions. In recent years, CanSinoBIO has been steadily advancing its international presence, promoting collaborations and the implementation of innovative achievements across Southeast Asia, the Middle East, North Africa, and the Americas. In Indonesia, the company is advancing inhaled tuberculosis vaccine development and the overseas launch and large-scale supply of the tetravalent meningococcal combination vaccine Menhycia®, while also conducting clinical studies to expand applicable populations and solidify commercial foundations. In Saudi Arabia and the broader Middle East and North Africa region, CanSinoBIO is facilitating product approval and commercialization while exploring joint R&D and localized production. In Malaysia, the company is developing an mRNA multivalent influenza vaccine in partnership with local institutions, leveraging its vaccine fill-and-finish facilities to support global influenza prevention.

He noted that vaccine development—from basic research and clinical trials to manufacturing and global supply chain management—is a highly coordinated, systemic process. Only by strategically integrating the entire industrial chain from the early stages of R&D can the “Valley of Death” between laboratory research and market application be effectively bridged, accelerating the delivery of innovative vaccines to public health.

Looking ahead, CanSinoBIO will continue to deepen its efforts in innovative vaccine R&D, strengthen global collaboration and technological coordination, and provide innovative, high-quality, and affordable vaccines to the world, continuously safeguarding human health.

Disclaimer:

This material is intended solely to share frontier information and research progress and does not constitute advertising or promotional content. The information contained herein is for reference purposes only. For the diagnosis and treatment of any disease, please follow the advice and guidance of physicians or other qualified healthcare professionals.

Information regarding the Company shall be subject to official announcements published through the Company's designated disclosure media and on the website of the Shanghai Stock Exchange. Investors are advised to make prudent decisions and remain mindful of investment risks.